Amphastar Pharmaceuticals (AMPH) Competitors $29.39 -1.42 (-4.61%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$29.87 +0.48 (+1.63%) As of 04:20 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock AMPH vs. NUVL, MRUS, CRSP, TGTX, ACAD, KRYS, CYTK, MENS, ADMA, and PCVXShould you be buying Amphastar Pharmaceuticals stock or one of its competitors? The main competitors of Amphastar Pharmaceuticals include Nuvalent (NUVL), Merus (MRUS), CRISPR Therapeutics (CRSP), TG Therapeutics (TGTX), ACADIA Pharmaceuticals (ACAD), Krystal Biotech (KRYS), Cytokinetics (CYTK), Jyong Biotech (MENS), ADMA Biologics (ADMA), and Vaxcyte (PCVX). These companies are all part of the "pharmaceutical products" industry. Amphastar Pharmaceuticals vs. Its Competitors Nuvalent Merus CRISPR Therapeutics TG Therapeutics ACADIA Pharmaceuticals Krystal Biotech Cytokinetics Jyong Biotech ADMA Biologics Vaxcyte Nuvalent (NASDAQ:NUVL) and Amphastar Pharmaceuticals (NASDAQ:AMPH) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, dividends, institutional ownership and analyst recommendations. Is NUVL or AMPH more profitable? Amphastar Pharmaceuticals has a net margin of 18.64% compared to Nuvalent's net margin of 0.00%. Amphastar Pharmaceuticals' return on equity of 20.76% beat Nuvalent's return on equity.Company Net Margins Return on Equity Return on Assets NuvalentN/A -32.58% -30.14% Amphastar Pharmaceuticals 18.64%20.76%9.68% Do institutionals & insiders hold more shares of NUVL or AMPH? 97.3% of Nuvalent shares are owned by institutional investors. Comparatively, 65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. 10.2% of Nuvalent shares are owned by insiders. Comparatively, 27.1% of Amphastar Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media prefer NUVL or AMPH? In the previous week, Nuvalent had 11 more articles in the media than Amphastar Pharmaceuticals. MarketBeat recorded 17 mentions for Nuvalent and 6 mentions for Amphastar Pharmaceuticals. Nuvalent's average media sentiment score of 1.39 beat Amphastar Pharmaceuticals' score of 1.22 indicating that Nuvalent is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvalent 12 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Amphastar Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer NUVL or AMPH? Nuvalent currently has a consensus price target of $119.36, suggesting a potential upside of 50.07%. Amphastar Pharmaceuticals has a consensus price target of $31.60, suggesting a potential upside of 7.52%. Given Nuvalent's stronger consensus rating and higher probable upside, research analysts plainly believe Nuvalent is more favorable than Amphastar Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvalent 0 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 3.08Amphastar Pharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40 Which has better earnings and valuation, NUVL or AMPH? Amphastar Pharmaceuticals has higher revenue and earnings than Nuvalent. Nuvalent is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNuvalentN/AN/A-$260.76M-$4.90-16.23Amphastar Pharmaceuticals$731.97M1.87$159.52M$2.6711.01 Which has more risk & volatility, NUVL or AMPH? Nuvalent has a beta of 1.29, suggesting that its stock price is 29% more volatile than the S&P 500. Comparatively, Amphastar Pharmaceuticals has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500. SummaryNuvalent and Amphastar Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks. Get Amphastar Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AMPH and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AMPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AMPH vs. The Competition Export to ExcelMetricAmphastar PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.42B$4.22B$5.77B$9.76BDividend YieldN/A1.29%6.66%4.49%P/E Ratio11.0111.1082.3826.60Price / Sales1.8715.28498.43159.38Price / Cash6.127.4225.7028.92Price / Book1.804.8111.056.56Net Income$159.52M-$109.62M$3.28B$266.04M7 Day Performance-2.88%0.25%0.12%-0.89%1 Month Performance37.34%16.60%8.96%4.34%1 Year Performance-37.33%30.27%53.91%24.06% Amphastar Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AMPHAmphastar Pharmaceuticals3.4016 of 5 stars$29.39-4.6%$31.60+7.5%-37.4%$1.42B$731.97M11.012,028Positive NewsNUVLNuvalent3.2307 of 5 stars$76.58+0.7%$120.80+57.7%-4.9%$5.52BN/A-15.6340Positive NewsAnalyst ForecastMRUSMerus3.003 of 5 stars$65.84-0.4%$88.75+34.8%+32.0%$4.98B$36.13M-11.9737News CoveragePositive NewsCRSPCRISPR Therapeutics3.5858 of 5 stars$51.83-2.3%$71.60+38.1%+16.4%$4.71B$37.31M-9.55460Positive NewsAnalyst RevisionTGTXTG Therapeutics4.3251 of 5 stars$29.33+1.3%$46.25+57.7%+40.2%$4.65B$329M79.27290News CoveragePositive NewsGap UpACADACADIA Pharmaceuticals4.0432 of 5 stars$25.99-0.9%$28.88+11.1%+57.2%$4.38B$957.80M19.54510Positive NewsAnalyst RevisionKRYSKrystal Biotech4.8083 of 5 stars$147.70-2.0%$210.38+42.4%-19.6%$4.27B$290.52M30.02210Positive NewsCYTKCytokinetics4.1761 of 5 stars$35.33-5.4%$71.58+102.6%-8.4%$4.23B$18.47M-6.93250Trending NewsAnalyst ForecastInsider TradeOptions VolumeMENSJyong BiotechN/A$54.81-1.3%N/AN/A$4.17BN/A0.0031News CoverageADMAADMA Biologics3.9279 of 5 stars$17.26-0.7%$27.67+60.3%+2.0%$4.12B$426.45M20.07530Positive NewsPCVXVaxcyte2.7844 of 5 stars$30.79+0.1%$136.50+343.3%-70.9%$4.00BN/A-7.49160News CoveragePositive News Related Companies and Tools Related Companies NUVL Competitors MRUS Competitors CRSP Competitors TGTX Competitors ACAD Competitors KRYS Competitors CYTK Competitors MENS Competitors ADMA Competitors PCVX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AMPH) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredThis Massive Market is Ripe for Disruption by this NasdaqFanatics Hit $31B. This Nasdaq Company Is Building the Next Wave Fanatics built a merch empire by owning th...i2i Marketing Group, LLC | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored“Shadow Group” in Washington, DC Could Crash MarketNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredWashington prepares for warWhile the headlines obsess over overseas conflicts, Washington has been quietly preparing for something much b...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amphastar Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amphastar Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
